Effect of early liraglutide administration on cardiometabolic risk factors in T2DM patients with coronary microvascular disease
10.3969/j.issn.1009-0126.2024.08.008
- VernacularTitle:利拉鲁肽对2型糖尿病伴冠状动脉微血管疾病患者心脏代谢危险因素的临床分析
- Author:
Hongxu ZHANG
1
;
Tong CHEN
;
Lifang ZHANG
;
Fanqi GENG
;
Zhao LI
;
Xuejuan ZHANG
Author Information
1. 266003 青岛大学附属医院全科医学科
- Keywords:
diabetes mellitus,type 2;
liraglutide;
cardiometabolic risk factors;
prognosis
- From:
Chinese Journal of Geriatric Heart Brain and Vessel Diseases
2024;26(8):892-897
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of early combined use of liraglutide on cardiometa-bolic risk factors and prognosis in patients with T2DM and CMVD.Methods A total of 124 T2DM patients with concomitant CMVD admitted in our hospital from May 2021 to June 2023 were enrolled,and divided into the liraglutide group(n=59)and the non-liraglutide group(n=65)according to taking liraglutide or not.The main observation indicators were compared between the two groups,including cardiometabolic risk factors,such as Hcy,UA,FPG,eGFR,HbA1c,hs-CRP,WC,BMI,WWI,and echocardiographic indicators,such as LAD,LVEDD,LVPWT,IVST,E/e',e',LVEF,LAVI,LVMI,and RWT.And the incidence of adverse reactions and read-mission rates were recorded during follow-up.Results After treatment,in the liraglutide group,Hcy,UA,FPG,HbA1c,hs-CRP,WC,BMI,WWI,E/e',LAVI,LVMI,RWT,IVST and LVPWT values,and anteroposterior,transverse and long diameters of left atrium were all lower than before treatment,and eGFR and e'value were increased(P＜0.05,P＜0.01),and no significant difference was seen in LVEF and LVEDD(P＞0.05).The non-liraglutide group obtained lower HbA1c,FPG,BMI,E/e'and LAVI values,and transverse diameter of left atrium,elevated LVPWT and e'value(P＜0.05,P＜0.01),and no obvious changes in Hcy,UA,eGFR,hs-CRP,WC,WWI,BMI,LVEF,LVMI,RWT,LVEDD,IVST,and anteroposterior and long diameters of left atrium when compared with the indicators before treatment(P＞0.05).At the end of the fol-low-up,when compared with the non-liraglutide group,the liraglutide group had more significant decreases in E/e',LAVI,LVMI and RWT values and increase in e'value(P＜0.05,P＜0.01),and higher total effective rates(94.92％vs 72.31％,P＜0.01).What's more,the readmission rate due to adverse cardiovascular events was notably lower in the liraglutide group and the non-liraglutide group(3.39％vs 15.38％,P＜0.05).Conclusion Compared with BMI,WWI may be more sensi-tive in reflecting changes in cardiometabolic risk factors in T2DM patients with CMVD;Early combined application of liraglutide has good efficacy and safety,and exerts multiple cardiovascular protective effects,including reducing cardiometabolic risk factors,improving cardiac diastolic function and renal function,inhibiting chronic inflammation and decreasing the occurrence of ad-verse cardiovascular events in the patients.
